MedPath

JAZZ PHARMACEUTICALS FRANCE

🇫🇷France
Ownership
-
Established
2003-01-01
Employees
-
Market Cap
-
Website
https://www.jazzpharma.com/careers/open-positions/

Xenon Pharmaceuticals Appoints Darren Cline as Chief Commercial Officer Ahead of Azetukalner Phase 3 Data

Xenon Pharmaceuticals has appointed Darren Cline as Chief Commercial Officer to lead commercial strategy for azetukalner, the company's lead Phase 3 candidate targeting epilepsy, major depressive disorder, and bipolar depression.

China Approves Zanidatamab as First Dual HER2-Targeted Bispecific Antibody for Biliary Tract Cancer

China's National Medical Products Administration granted conditional approval to zanidatamab for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, marking the first dual HER2-targeted bispecific antibody approved for this indication in China.

Zepzelca-Tecentriq Combination Shows Survival Benefit in Metastatic Small Cell Lung Cancer

Phase 3 trial results reveal that combining Zepzelca with Tecentriq as maintenance therapy extended median progression-free survival to 5.4 months versus 2.1 months with Tecentriq alone in metastatic small cell lung cancer patients.

Komodo Health's Real-World Evidence Platform Powers 31 Research Studies at ISPOR 2025

Komodo Health's healthcare intelligence platform enabled 31 research studies presented at the 2025 ISPOR global conference, including three studies led by Komodo researchers and 27 collaborative studies with academic institutions and Life Sciences companies.

Tarlatamab Shows Superior Survival in Small Cell Lung Cancer: Key Highlights from ASCO 2025

Amgen's tarlatamab (Imdelltra) demonstrated superior overall survival compared to standard chemotherapy in relapsed small cell lung cancer patients, potentially establishing a new second-line treatment standard.

Jazz Pharmaceuticals Reports Strong Q1 2025 Performance with $898 Million in Revenue, Advances Pipeline with Zepzelca sNDA Submission

• Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively. • The company submitted a supplemental New Drug Application for Zepzelca in combination with atezolizumab as maintenance therapy for first-line extensive-stage small cell lung cancer, based on promising Phase 3 trial results. • Jazz completed the acquisition of Chimerix, adding dordaviprone to its late-stage pipeline for H3 K27M-mutant diffuse glioma, with an FDA PDUFA target date of August 18, 2025.

Avadel Wins Federal Circuit Appeal: Path Cleared for LUMRYZ Development in Idiopathic Hypersomnia

The U.S. Court of Appeals for the Federal Circuit has overturned key portions of a Delaware Court injunction, allowing Avadel Pharmaceuticals to seek FDA approval for LUMRYZ in idiopathic hypersomnia.

PharmaMar Seeks EU Fast-Track Status for Lurbinectedin-Tecentriq Combination in Extensive-Stage SCLC

PharmaMar has applied for accelerated assessment from the European Medicines Agency for lurbinectedin in combination with Roche's Tecentriq (atezolizumab) for extensive-stage small cell lung cancer.

Elraglusib Shows Promise for Advanced Salivary Gland Carcinoma in Upcoming AACR Presentation

Actuate Therapeutics will present Phase II clinical trial data on elraglusib, their GSK-3β inhibitor, for advanced salivary gland carcinoma at the AACR Annual Meeting 2025 in Chicago.

Jazz and Hikma to Pay $195M to Settle Antitrust Claims Over Narcolepsy Drug Xyrem

Jazz Pharmaceuticals will pay $145 million to settle allegations of anti-competitive practices related to its narcolepsy drug Xyrem, while denying all wrongdoing in the class action lawsuit.

© Copyright 2025. All Rights Reserved by MedPath